MetaCap

Schrodinger (SDGR) vs Stoke Therapeutics (STOK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Schrodinger (SDGR) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 39.2% versus a loss of 8.6%. Over five years, STOK leads with a +6.8% price change compared with -42.0% for SDGR. Stoke Therapeutics is the larger company by market cap ($1.75 billion vs $1.72 billion), about 1.0 times the size.

Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -40.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SDGR+39.22%STOK-8.62%
+110%+35%-40%
Nov 21, 20251 yearNov 20, 2026
SDGR-43.80%STOK-3.56%
+40%-27%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SDGR versus STOK key metrics
MetricSDGRSTOK
Share price$22.93$26.81
Market cap$1.72B$1.75B
1-day change-12.95%-0.45%
YTD return+28.24%-15.53%
1-year return+39.22%-8.62%
5-year return-42.01%+6.77%
EPS (TTM)$-0.79$-3.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$255.87M$184.42M
Revenue growth (YoY)+23.29%+404.50%
Net income (latest FY)$-103.27M$-6.88M
Gross margin55.74%—
Operating margin-65.23%-11.16%
Net margin-40.36%-3.73%
52-week high$34.00$40.22
52-week low$10.95$22.05
Distance from 52-week high-32.56%-33.34%
Analyst consensusbuystrong_buy
Avg. price target upside+46.40%+73.00%
Average volume2.08M1.02M
Shares outstanding65.91M65.41M
Employees850170
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SDGR has outperformed STOK by 47.8 percentage points over the past year.
  • Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -40.4 cents for Schrodinger.
  • Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +23.29%).

About Schrodinger

SDGR stock →

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees

About Stoke Therapeutics

STOK stock →

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees

SDGR vs STOK FAQ

Which is bigger, Schrodinger or Stoke Therapeutics?

Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.75B compared with $1.72B for Schrodinger (SDGR).

Which stock has performed better over the past year, SDGR or STOK?

SDGR returned +39.22% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.

Are Schrodinger and Stoke Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons